Literature DB >> 10985881

Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.

M J Casey1, C Bewtra, L L Hoehne, A D Tatpati, H T Lynch, P Watson.   

Abstract

OBJECTIVE: The literature reports conflicting studies claiming premalignant histological features in benign ovaries from women who may have hereditary predilections for ovarian carcinoma. To test the veracity of these claims, this investigation studied ovaries prophylactically removed from members of hereditary breast ovarian cancer (HBOC) syndrome families who carry BRCA1 and BRCA2 mutations and compared these with the ovaries of mutation-negative women from the same HBOC syndrome kindred.
METHODS: Sixty cases of women from HBOC syndrome families who had undergone prophylactic oophorectomies and whose BRCA1 and BRCA2 mutation status had been tested were selected from our database. Thirty had tested positive for BRCA1 mutations, 3 carried BRCA2 mutations, and 27 were negative for both BRCA1 and BRCA2 germline mutations. Histologic material from each case was examined by light microscopy blinded to the mutation status. Histologic features, previously reported to be possible precursor lesions for ovarian cancer, were quantified. Data from BRCA1 and BRCA2 mutation carriers were compared with those from mutation-negative cases in the direct line of genetic inheritance from the same HBOC syndrome families.
RESULTS: Statistical analysis found that a more frequent occurrence of ovarian surface micropapillae in 87% of mutation carriers compared with just 55% of mutation-negative cases was the only histologic feature which was significantly different between the two groups (P = 0.39). Cortical clefts tended to be deeper in the ovaries of mutation carriers, but this did not reach significance (P = 0.051). There were no other significant histologic differences between the ovaries removed from mutation carriers and those from noncarriers.
CONCLUSIONS: The results of our large and prospectively controlled, blinded study contrast with those reported from smaller, unblinded investigations. Except for the possible biological significance of surface micropapillae on ovaries from BRCA1 and BRCA2 mutation carriers, we found no histologic evidence for a genetically determined ovarian carcinoma precursor lesion. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10985881     DOI: 10.1006/gyno.2000.5861

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  10 in total

Review 1.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact.

Authors:  Keren Levanon; Christopher Crum; Ronny Drapkin
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

Review 2.  Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.

Authors:  Henry T Lynch; Murray Joseph Casey; Carrie L Snyder; Chhanda Bewtra; Jane F Lynch; Matthew Butts; Andrew K Godwin
Journal:  Mol Oncol       Date:  2009-02-21       Impact factor: 6.603

3.  Epidemiologic correlates of ovarian cortical inclusion cysts (CICs) support a dual precursor pathway to pelvic epithelial cancer.

Authors:  Ann K Folkins; Aasia Saleemuddin; Leslie A Garrett; Judy E Garber; Michael G Muto; Shelley S Tworoger; Christopher P Crum
Journal:  Gynecol Oncol       Date:  2009-07-16       Impact factor: 5.482

Review 4.  Role of versican, hyaluronan and CD44 in ovarian cancer metastasis.

Authors:  Miranda P Ween; Martin K Oehler; Carmela Ricciardelli
Journal:  Int J Mol Sci       Date:  2011-01-31       Impact factor: 5.923

Review 5.  Development of a mouse model of menopausal ovarian cancer.

Authors:  Elizabeth R Smith; Ying Wang; Xiang-Xi Xu
Journal:  Front Oncol       Date:  2014-02-26       Impact factor: 6.244

Review 6.  BRCA mutations in the manifestation and treatment of ovarian cancer.

Authors:  Zimin Pan; Xing Xie
Journal:  Oncotarget       Date:  2017-05-30

7.  A transcriptome-wide association study of high-grade serous epithelial ovarian cancer identifies new susceptibility genes and splice variants.

Authors:  Alexander Gusev; Kate Lawrenson; Xianzhi Lin; Paulo C Lyra; Siddhartha Kar; Kevin C Vavra; Felipe Segato; Marcos A S Fonseca; Janet M Lee; Tanya Pejovic; Gang Liu; Beth Y Karlan; Matthew L Freedman; Houtan Noushmehr; Alvaro N Monteiro; Paul D P Pharoah; Bogdan Pasaniuc; Simon A Gayther
Journal:  Nat Genet       Date:  2019-05-01       Impact factor: 38.330

8.  Identification of Tumor Microenvironment Scoring Scheme Based on Bioinformatics Analysis of Immune Cell Infiltration Pattern of Ovarian Cancer.

Authors:  Xiao Huo; Mo Yang; Xi Zhang; Shuzhen Wang; Hengzi Sun
Journal:  J Oncol       Date:  2022-08-30       Impact factor: 4.501

Review 9.  Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management.

Authors:  Ashwin R Sama; Russell J Schilder
Journal:  Int J Womens Health       Date:  2014-01-28

10.  YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells.

Authors:  G Hua; X Lv; C He; S W Remmenga; K J Rodabough; J Dong; L Yang; S M Lele; P Yang; J Zhou; A Karst; R I Drapkin; J S Davis; C Wang
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.